Final Results for year-ended 31 December 2008

Cyprotex Delivers maiden operating profit

Cyprotex (AIM:CRX), the drug discovery technology and information company, today reports its final results for the year ended 31 December 2008. Cyprotex enables its customers to access secure, high quality Absorption, Distribution, Metabolism, Excretion / Toxicity (ADMET) data without incurring significant overheads. Its highly automated platform guarantees high throughput, reproducibility and rapid turnaround of ADMET data, setting new industry standards for this sector of the market.

Highlights

• Revenues increased by 43% to £5.18 million (2007: £3.63 million)
• Gross profits rose by 49% to £4.48 million (2007: £3.00 million)
• Maiden operating profit of £567,000 (2007: loss of £496,000)
• Earnings per share of 0.36 pence (2007: loss per share of 0.35 pence)
• Successful fully subscribed Placing and Open Offer raised £1.00 million (£0.97 million net of costs) in August 2008                                   
• Year end cash position improved significantly to £1.58 million notwithstanding continued investment (2007: £0.3 million)

Steve Harris, Chairman of Cyprotex, said:

“We are pleased to announce a significant increase in revenues and our maiden profit in 2008. Going forward we plan to expand the business both organically through strengthening relationships with our customers and selective collaborations, and through M&A activity.”

Download Cyprotex Final Results for year ended 31 December 2008

For further information:
Cyprotex PLC

Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Noble & Company
John Llewellyn-Lloyd
Tel: +44 (0) 20 7763 2200
john.llewellyn-lloyd@noblegp.com
Sam Reynolds
Tel: +44 (0) 20 7763 2200
sam.reynolds@noblegp.com
www.noblegp.com

Financial Dynamics
Ben Brewerton / John Dineen
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com